EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Emma C Bernsen iD, Eugène T P Verwiel iD, Maaike van der Lee iD, Jesse J Swen iD, Marcel Santoso iD, Leiah J Brigitha iD, Rick Admiraal iD, Bastiaan B J Tops iD, Alwin D R Huitema iD, Patrick Kemmeren iD, Jayne Y Hehir-Kwa iD, Lidwien M Hanff iD und 1 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Emma C Bernsen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Neoplasms, Antineoplastic Agents, Pharmacogenetics. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for a subset of supportive care drugs and anticancer drugs, including thiopurines, irinotecan, capecitabine, and 5‐fluorouracil. In this study, we evaluate the potential impact of pre‐emptive pharmacogenetic screening by retrospectively identifying opportunities for dose or treatment adjustments within a national pediatric oncology cohort. Our analysis focused on ten genes and 28 drugs relevant to pediatric oncology, which are included in the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group guidelines. In a cohort of 1,151 pediatric oncology subjects, we identified that 16% of individuals could have benefited from altered drug dosing or treatment. These include dose and treatment recommendations for allopurinol, nonsteroidal anti‐inflammatory drugs, phenytoin, amitriptyline, proton pump inhibitors, voriconazole, tramadol, codeine, paroxetine, tacrolimus, rasburicase, and 6‐mercaptopurine. As genetic data increasingly becomes available through molecular diagnostics in pediatric oncology, there is a unique opportunity to re‐utilize this data for pre‐emptive pharmacogenetic screening. Leveraging genetic profiles to guide clinicians in drug selection and dose optimization can improve patient outcomes by enhancing the safety and efficacy of treatments. We therefore recommend incorporating pharmacogenetic screening into clinical workflows to advance personalized medicine in pediatric oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingNeoplasmsAntineoplastic AgentsPharmacogeneticsHumansChildRetrospective StudiesFemaleMaleAdolescentChild, PreschoolInfantPrecision MedicineCohort Studies

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Emma C Bernsen, Eugène T P Verwiel, Maaike van der Lee, Jesse J Swen, Marcel Santoso, Leiah J Brigitha, Rick Admiraal, Bastiaan B J Tops, Alwin D R Huitema, Patrick Kemmeren, Jayne Y Hehir-Kwa, Lidwien M Hanff, Meta H M Diekstra

Zitieren

APA

Bernsen, E. C., Verwiel, E. T. P., van der Lee, M., Swen, J. J., Santoso, M., Brigitha, L. J., Admiraal, R., Tops, B. B. J., Huitema, A. D. R., Kemmeren, P., Hehir-Kwa, J. Y., Hanff, L. M., & Diekstra, M. H. M. (2025). Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3685

Vancouver

Bernsen EC, Verwiel ETP, van der Lee M, Swen JJ, Santoso M, Brigitha LJ, et al. Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3685

BibTeX
@article{Bernsen2025,
  author = {Bernsen, Emma C and Verwiel, Eugène T P and van der Lee, Maaike and Swen, Jesse J and Santoso, Marcel and Brigitha, Leiah J and Admiraal, Rick and Tops, Bastiaan B J and Huitema, Alwin D R and Kemmeren, Patrick and Hehir-Kwa, Jayne Y and Hanff, Lidwien M and Diekstra, Meta H M},
  title = {Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3685}
}
Kostenlos starten →